New Knowledge and Challenges in Breast Cancer

Message from the Guest Editor

The treatment of breast cancer presents many challenges in both diagnosis and treatment. Radiomics and genomics offer opportunities to select patients for the most appropriate treatments and allow glimpses of new scenarios. Increasingly, knowledge on the characteristics of tumor subtypes makes it possible to predict responses to treatments and to select the most appropriate courses of treatment. Increasingly, targeted cancer treatments and new technical advances in surgical treatments allow us to glimpse an increasingly personalized future of breast cancer care that respects the integrity of the person. Let us prepare to change the nomenclature of breast cancers.
Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
@JPM_MDPI